Rome, 28 June. (askanews) – Change of pace for patients with advanced non-small cell lung cancer (NSCLC) and KRAS p.G12C mutation. Sotorasib, the first oral target therapy specific for this mutation, has obtained reimbursement in Italy. In 2023, Italy records 44,000 new diagnoses of lung cancer, with a higher prevalence in men (30,000 cases) than in women (14,000 cases). 85% of cases belong to the category of non-small cell lung cancer (NSCLC), a form which, in 60% of cases, presents genetic mutations, including those involving KRAS which are among the most widespread, with an incidence of 30%. In particular, the G12C mutation accounts for almost half of all KRAS mutations, representing 12-13% of total cases in NSCLC: in practice, one patient out of every 8 presents this mutation, with an overall estimate that counts every year. around 2600 people. Overall in lung cancer, 5-year survival (currently 16%) is increasing thanks to the use in clinical practice of target therapies, which are more effective and better tolerated than chemotherapy alone: and sotorasib represents the first therapy oral target for patients with advanced NSCLC and KRAS p.G12C mutation who until now were without specific treatment. The teacher. Silvia Novello, Director of the Thoracic Oncology Unit, San Luigi di Orbassano (TO) Professor of Medical Oncology, University of Turin, explains: “With the reimbursement indication of Sotorasib, an important therapeutic opportunity opens up for patients suffering from non-specific lung cancer. advanced-stage small cells with KRAS p.G12C mutation, who have already undergone first-line treatment. This is thanks to the results of the CodeBreak 100 study which demonstrated an advantage in terms of time to progression for these patients. , one-year survival and also in terms of tolerability compared to standard treatment”. In fact, sotorasib reduces the risk of disease progression by 34% and doubles the progression-free survival rate at 12 months; important data capable of providing an answer to a great need that is still unmet for patients who have so far been treated with chemotherapy alone.
